Legal Representation
Attorney
DONNA J. BUNTON
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 23, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jul 23, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 20, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jun 20, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jun 18, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 18, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 18, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 9, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Nov 9, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Aug 9, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2023 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jul 19, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jul 19, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 23, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jun 23, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 2, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 28, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Feb 28, 2023 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Feb 28, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 2, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 31, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 31, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 31, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 2, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 28, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 28, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 28, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 31, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 20, 2021 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Jul 20, 2021 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Jul 20, 2021 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Jul 23, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 29, 2020 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Jan 9, 2020 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Dec 31, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 31, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 11, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 25, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 22, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 9, 2019 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Sep 6, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 26, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant, all of the foregoing primarily available by prescription
First Use Anywhere:
Jun 7, 2023
First Use in Commerce:
Jun 7, 2023
Class 042
Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS
First Use Anywhere:
20190900
First Use in Commerce:
20190900
Additional Information
Pseudo Mark
AIM IMMUNOLOGICAL TECH
Classification
International Classes
005
042